Novo Nordisk, one of the largest
companies in the world in diabetes care, presently accounts for 55
percent of the insulin market in India
Melvin Oscar D' Souza
care, growth hormone and homeostasis maintenance products
Plot No.32, 47-50,
EPIP Area, Whiltefield,
Bangalore - 560 066
The growth of the insulin market in India
helped Novo Nordisk register a growth of 27.62 percent with sales
462 crore in FY 2010-11 as compared to
year's revenue of
362 crore. Novo Nordisk India, which is
with diabetes care in India, continues to lead the insulin market with
over 55 percent of the market share.
Established in the year 1990, Novo Nordisk India is a subsidiary of
Novo Nordisk, one of the largest companies in the world leading in the
domain of diabetes care products. It claims to be introducing products
and services that have never before been seen in the treatment of
diabetes in India.
With products in diabetes care, homeostasis management and hormone
replacement therapy, Novo Nordisk, has since the last decade tried to
change the way people live, when they are struck by these unfortunate
but alarmingly common diseases.
Novo Nordisk is seeking to change the future course of diabetes by
using innovation to produce novel methods of diagnosis and treatment
for diabetes. Novo Nordisk has already produced an array of products
that could be used to treat and monitor diabetes. To help treat
diabetic patients, Novo Nordisk has come up with a range of
biopharmaceuticals like modern insulin, NovoNorm and Glucagen Hypokit.
Apart from biopharmaceuticals, the company also introduced insulin
delivery devices like durable pen and prefilled pen. The company boasts
of revolutionizing treatment of diabetes with the introduction of the
dial-insert-push technology of insulin delivery.
Homeostasis management, which is one of the areas of focus for Novo
Nordisk, has influenced the company to produce a recombinant factor
VIIa, NovoSeven, for the treatment of hemophilia A and B, an essential
product for patients whose blood fails to coagulate at the appropriate
Another area of focus for the company is growth hormone therapy. Novo
Nordisk has produced devices to help patients suffering from growth
hormone deficiencies like Turner's syndrome and chronic renal disease
with the help of their products like Norditropin Nordilet.
Novo Nordisk says it will to help the people who are suffering from
diabetes. In this regard the company has established and maintained
partnerships with external organizations. As a part of its global
initiatives, the company launched Diabetes Awareness Wishes and Needs
(DAWN), programme in India. The programme is based on the largest
global survey of the psychosocial aspects of diabetes until date. It
involves more than 5,000 diabetic people and 3,800 healthcare
professionals in 13 countries. It is a global Novo Nordisk initiative
in collaboration with the International Diabetes Federation and an
expert advisory panel. Today, the initiative conducts activities in
more than 30 countries.